- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Gary Owens: Payers Need to Be Doing More for Patients With PAH
Gary Owens, MD, president of Gary Owens Associates, addresses how payers can improve outcomes for persons who have pulmonary arterial hypertension (PAH).
Gary Owens, MD, president of Gary Owens Associates, talks next steps payers can take to improve outcomes among persons living with pulmonary arterial hypertension (PAH), including stepping up education effort and improving medication access.
Transcript
What can payers do to make progress against PAH?
This is a disease that is often misunderstood, underrecognized, and underdiagnosed. Hence, that 2- to 3-year journey from symptom onset. So I think payers can hopefully play a role here, too, by helping educate the community. Now, the problem is, trying to get this message across to primary care physicians who are very, very busy with many other things, including the COVID-19 pandemic.
It’s easily possible for a disease that affects 5 to 10 per 1 million to get lost in the shuffle. But I think what it really does say, when these patients are identified by payers, getting case managers involved, and getting those case managers to coordinate that team approach I talked about, as well as making sure that patients have access to the proper pharmaceutical care, is what payers could and should be doing. Not only now but going forward.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Study Suggests Postdischarge Care Needs Targeted, Multifaceted Approaches
January 15th 2025The findings challenge the effectiveness of these widely used transitional care interventions and suggest a need for more targeted, multifaceted approaches to address the needs of higher-risk patients.
Read More
